Forwarded from برنامج تطوير مهنة الصيدلة - PPDPROGRAM
Forwarded from PPDPROGRAM-GOOD PHARMACY PRACTICE
Community pharmacy services
In 2014, PHE developed an action plan, in partnership with government, the NHS, volunteer groups and academia, to improve the prevention, early detection and management of high blood pressure in England. In 2017, it produced a report[2] in collaboration with Pharmacy Voice to highlight the public health role of community pharmacists and the impact they can have in improving the detection and management of hypertension.
Blood pressure is a significant factor [in stroke] and people don’t always know that their blood pressure is raised
One example in the report is the collaboration between Well Pharmacy, the third largest pharmacy chain in the UK, and the Stroke Association, the UK’s leading stroke charity, which started at the beginning of 2017. “Blood pressure is a significant factor [in stroke] and people don’t always know that their blood pressure is raised,” explains Jane Devenish, an NHS Services and Standards pharmacist at Well Pharmacy. “We thought that by working with the Stroke Association we could make a big impact on preventing people from having strokes.”
Devenish believes strongly that community pharmacists are well placed to be able to identify hypertension at the earliest opportunity and help patients make the necessary lifestyle changes to reduce their risk of serious cardiovascular events.
“[Community pharmacists] see a variety of people at all stages of their life: when they are well, when they’re concerned about their health and when they have long-term conditions,” she explains. “If you can pick up that someone’s got elevated blood pressure before they start to have symptoms, they have the opportunity to do something about it at that stage — it’s about giving people the right information at the right time.” As part of the initiative, Well Pharmacy offers free blood pressure checks, which include making lifestyle recommendations that are realistic for individuals and their circumstances.
In 2014, PHE developed an action plan, in partnership with government, the NHS, volunteer groups and academia, to improve the prevention, early detection and management of high blood pressure in England. In 2017, it produced a report[2] in collaboration with Pharmacy Voice to highlight the public health role of community pharmacists and the impact they can have in improving the detection and management of hypertension.
Blood pressure is a significant factor [in stroke] and people don’t always know that their blood pressure is raised
One example in the report is the collaboration between Well Pharmacy, the third largest pharmacy chain in the UK, and the Stroke Association, the UK’s leading stroke charity, which started at the beginning of 2017. “Blood pressure is a significant factor [in stroke] and people don’t always know that their blood pressure is raised,” explains Jane Devenish, an NHS Services and Standards pharmacist at Well Pharmacy. “We thought that by working with the Stroke Association we could make a big impact on preventing people from having strokes.”
Devenish believes strongly that community pharmacists are well placed to be able to identify hypertension at the earliest opportunity and help patients make the necessary lifestyle changes to reduce their risk of serious cardiovascular events.
“[Community pharmacists] see a variety of people at all stages of their life: when they are well, when they’re concerned about their health and when they have long-term conditions,” she explains. “If you can pick up that someone’s got elevated blood pressure before they start to have symptoms, they have the opportunity to do something about it at that stage — it’s about giving people the right information at the right time.” As part of the initiative, Well Pharmacy offers free blood pressure checks, which include making lifestyle recommendations that are realistic for individuals and their circumstances.
Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor:
Over the past decade, infections caused by multidrug-resistant Gram-negative organisms have increased. The limited availability in treatment options for these infections prompted both the UK to create a five-year antimicrobial resistance strategic plan to stimulate the development of new antibiotics, and the Infectious Diseases Society of America to call for ten new antimicrobial agents to be developed by 2020. Ceftazidime-avibactam is a combination of a third-generation .
Over the past decade, infections caused by multidrug-resistant Gram-negative organisms have increased. The limited availability in treatment options for these infections prompted both the UK to create a five-year antimicrobial resistance strategic plan to stimulate the development of new antibiotics, and the Infectious Diseases Society of America to call for ten new antimicrobial agents to be developed by 2020. Ceftazidime-avibactam is a combination of a third-generation .
https://news.1rj.ru/str/ppdprogram/535
WHO recommends new categories for antibiotics to tackle resistance:
The Pharmaceutical Journal12 JUN 2017By Emma Wilkinson
The biggest change to the drug class in the 40-year history of the essential medicines list is an effort to preserve the effectiveness of ‘last resort’ medicines.
The World Health Organization (WHO) has split antibiotics into three categories — access, watch and reserve — in its latest essential medicines list to help ensure the right antibiotics are used for the right infections.
Medicines for HIV, hepatitis C, tuberculosis, and leukaemia are also among 30 new medicines added to the 2017 list, ‘WHO model list of essential medicines’, bringing its total essential medicines to 433.
The review of antibiotics, which is the biggest change to the drug class in the 40-year history of the essential medicines list, is part of efforts to fight drug resistance and preserve the effectiveness of ‘last resort’ medicines, WHO says.
Those in the ‘access’ category, which include amoxicillin for pneumonia, should be available at all times; the ‘watch’ category includes those that are recommended as first or second-line treatment for a small number of infections, such as ciprofloxacin in the treatment of cystitis; and the ‘reserve’ category includes antibiotics such as colistin and some cephalosporins that should only be used in severe circumstances, when other options have failed.
The updated list includes 10 antibiotics for adults, and 12 for children.
Other new additions include dasatinib and nilotinib for resistant chronic myeloid leukaemia, sofosbuvir plus velpatasvir as the first combination therapy to treat all six types of hepatitis C, HIV drug dolutegravir, and pre-exposure prophylaxis (PrEP) with tenofovir alone, or in combination with emtricitabine or lamivudine.
WHO experts have also included delamanid in the 2017 update for the treatment of children and adolescents with multidrug-resistant tuberculosis and clofazimine for children and adults with the disease.
For children, the list now includes child-friendly, fixed-dose combination formulations of isoniazid, rifampicin, ethambutol and pyrazinamide.
And fentanyl skin patches and methadone for pain relief in cancer patients have been added with the aim of increasing access to medicines for end-of-life care.
“Safe and effective medicines are an essential part of any health system,” says Marie-Paule Kieny, WHO assistant director-general for health systems and innovation.
“Making sure all people can access the medicines they need, when and where they need them, is vital to countries’ progress towards universal health coverage.”
Suzanne Hill, director of essential medicines and health products adds: “The rise in antibiotic resistance stems from how we are using — and misusing — these medicines.
“The new WHO list should help health system planners and prescribers ensure people who need antibiotics have access to them, and ensure they get the right one, so that the problem of resistance doesn’t get worse.”
Helen Stokes-Lampard, chair of the Royal College of GPs, says the profession welcomes the WHO taking action to tackle growing resistance to antibiotics.
“GPs and other prescribers must have access to guidance and tools that help us prescribe safely for all conditions, in the best interests of individual patients and public health globally — and this updated ‘Essential medicines list’ should be useful in our daily practice.
“It’s important that the list is constantly evaluated and updated as new research is published, in a way that best preserves the efficacy of the drugs we have available to us for as long as possible, in the long-term interests of the health of our global population.”
She concludes: “What is also necessary is for more investment and research into developing new drugs, particularly antibiotics, so that we have more options available to tackle emerging diseases, so that we can keep our patients safe for years to come.”
WHO recommends new categories for antibiotics to tackle resistance:
The Pharmaceutical Journal12 JUN 2017By Emma Wilkinson
The biggest change to the drug class in the 40-year history of the essential medicines list is an effort to preserve the effectiveness of ‘last resort’ medicines.
The World Health Organization (WHO) has split antibiotics into three categories — access, watch and reserve — in its latest essential medicines list to help ensure the right antibiotics are used for the right infections.
Medicines for HIV, hepatitis C, tuberculosis, and leukaemia are also among 30 new medicines added to the 2017 list, ‘WHO model list of essential medicines’, bringing its total essential medicines to 433.
The review of antibiotics, which is the biggest change to the drug class in the 40-year history of the essential medicines list, is part of efforts to fight drug resistance and preserve the effectiveness of ‘last resort’ medicines, WHO says.
Those in the ‘access’ category, which include amoxicillin for pneumonia, should be available at all times; the ‘watch’ category includes those that are recommended as first or second-line treatment for a small number of infections, such as ciprofloxacin in the treatment of cystitis; and the ‘reserve’ category includes antibiotics such as colistin and some cephalosporins that should only be used in severe circumstances, when other options have failed.
The updated list includes 10 antibiotics for adults, and 12 for children.
Other new additions include dasatinib and nilotinib for resistant chronic myeloid leukaemia, sofosbuvir plus velpatasvir as the first combination therapy to treat all six types of hepatitis C, HIV drug dolutegravir, and pre-exposure prophylaxis (PrEP) with tenofovir alone, or in combination with emtricitabine or lamivudine.
WHO experts have also included delamanid in the 2017 update for the treatment of children and adolescents with multidrug-resistant tuberculosis and clofazimine for children and adults with the disease.
For children, the list now includes child-friendly, fixed-dose combination formulations of isoniazid, rifampicin, ethambutol and pyrazinamide.
And fentanyl skin patches and methadone for pain relief in cancer patients have been added with the aim of increasing access to medicines for end-of-life care.
“Safe and effective medicines are an essential part of any health system,” says Marie-Paule Kieny, WHO assistant director-general for health systems and innovation.
“Making sure all people can access the medicines they need, when and where they need them, is vital to countries’ progress towards universal health coverage.”
Suzanne Hill, director of essential medicines and health products adds: “The rise in antibiotic resistance stems from how we are using — and misusing — these medicines.
“The new WHO list should help health system planners and prescribers ensure people who need antibiotics have access to them, and ensure they get the right one, so that the problem of resistance doesn’t get worse.”
Helen Stokes-Lampard, chair of the Royal College of GPs, says the profession welcomes the WHO taking action to tackle growing resistance to antibiotics.
“GPs and other prescribers must have access to guidance and tools that help us prescribe safely for all conditions, in the best interests of individual patients and public health globally — and this updated ‘Essential medicines list’ should be useful in our daily practice.
“It’s important that the list is constantly evaluated and updated as new research is published, in a way that best preserves the efficacy of the drugs we have available to us for as long as possible, in the long-term interests of the health of our global population.”
She concludes: “What is also necessary is for more investment and research into developing new drugs, particularly antibiotics, so that we have more options available to tackle emerging diseases, so that we can keep our patients safe for years to come.”
FDA requests first opioid removal from market after abuse sparks HIV outbreak:
The Pharmaceutical Journal14 JUN 2017
The US Food and Drug Administration (FDA) has requested that a formulation of oxymorphone hydrochloride, marketed as Opana ER, be withdrawn from the market due to abuse, saying that the benefits of the product no longer outweigh the risks.
The drug was voluntarily reformulated by the manufacturer Endo Pharmaceuticals in 2012 with a tablet coating to prevent abuse through snorting.
https://news.1rj.ru/str/ppdprogram/538
The Pharmaceutical Journal14 JUN 2017
The US Food and Drug Administration (FDA) has requested that a formulation of oxymorphone hydrochloride, marketed as Opana ER, be withdrawn from the market due to abuse, saying that the benefits of the product no longer outweigh the risks.
The drug was voluntarily reformulated by the manufacturer Endo Pharmaceuticals in 2012 with a tablet coating to prevent abuse through snorting.
https://news.1rj.ru/str/ppdprogram/538
Ustekinumab approved by NICE for treatment of Crohn’s disease:
The Pharmaceutical Journal26 JUN 2017
The National Institute of Health and Care Excellence (NICE), England’s health technology assessment body, has approved ustekinumab (Stelara; Janssen) as a treatment for patients with moderate to severe Crohn’s disease who have had little or no response, or an intolerance, to existing therapies.
Ustekinumab is a human monoclonal antibody treatment that works by binding to specific proteins on cells, called interleukin-21 (IL-21) and IL-23, to stop the production of cytokines that trigger the inflammatory response in the body. It has already been recommended by NICE as a treatment for psoriasis and psoriatic arthritis and evidence now shows that it can improve the quality of life among patients with Crohn’s.
“Crohn’s disease can have a debilitating impact on a person’s quality of life, from self-esteem through to experiencing regular relapses,” says Carole Longson, director of the health technology evaluation centre at NICE.
“Ustekinumab provides a convenient and viable option for patients with Crohn’s. It is a new way of treating the disease compared with conventional treatment, and can be used where other options have already been tried and stopped working.”
The final draft of the NICE guidance is now under consultation and will be open for appeal until 30 June 2017. If published, the NHS will then be expected to provide the medication within three months.
https://news.1rj.ru/str/ppdprogram/553
The Pharmaceutical Journal26 JUN 2017
The National Institute of Health and Care Excellence (NICE), England’s health technology assessment body, has approved ustekinumab (Stelara; Janssen) as a treatment for patients with moderate to severe Crohn’s disease who have had little or no response, or an intolerance, to existing therapies.
Ustekinumab is a human monoclonal antibody treatment that works by binding to specific proteins on cells, called interleukin-21 (IL-21) and IL-23, to stop the production of cytokines that trigger the inflammatory response in the body. It has already been recommended by NICE as a treatment for psoriasis and psoriatic arthritis and evidence now shows that it can improve the quality of life among patients with Crohn’s.
“Crohn’s disease can have a debilitating impact on a person’s quality of life, from self-esteem through to experiencing regular relapses,” says Carole Longson, director of the health technology evaluation centre at NICE.
“Ustekinumab provides a convenient and viable option for patients with Crohn’s. It is a new way of treating the disease compared with conventional treatment, and can be used where other options have already been tried and stopped working.”
The final draft of the NICE guidance is now under consultation and will be open for appeal until 30 June 2017. If published, the NHS will then be expected to provide the medication within three months.
https://news.1rj.ru/str/ppdprogram/553
Forwarded from برنامج تطوير مهنة الصيدلة - PPDPROGRAM
حركية الدواء السريرية
Clinical Pharmacokinetics :
حركية الدواء السريرية مقرر من أهم مقررات كلية الصيدلة وتوصيف المقرر والمفردات تشمل إمتصاص الدواء والتوفر الحيوي وتوزيع الدواء وإستقلاب الدواء وطرد الدواء من الجسم و دراسة حركية الدواء من حيث تقييم أسس حركية الدواء الذي تحدد المدى المحدد لفعالية الدواء وتنظيم الجرعات و المتابعة المستمرة لنتائج الدواء مع المريض. دراسة حركية الدواء لها علاقة بصياغة وتحضير الدواء و تحليل الدواء وإستخدام الدواء ومعلومات الدواء الأساسية .
تطبيق مبادئ الحركة الدوائية في الحالات المرضية بشكل أساسي يركز هذا المقرر على نواحي وأسس الحركة الدوائية في اختيار الجرعات الدوائية المناسبة لكل مريض على النحو الأمثل. يناقش أيضا مبادئ الحركة الدوائية السريرية وتطبيقاتها في علاج الأمراض المختلفة كما يشير إلى التغيرات في حركية الدواء نتيجة للحالات المرضية بحيث يتم التركيز على متابعة تراكيز الدواء في الدم والطرق المتبعة في تخصيص الجرعات للمرضى وتأثير ذلك من الناحية العلاجية.
يتضمن هذا المقرر تعليم مبادئ حركية الدواء السريرية والمساعدة في تحديد نظام الجرعات وتقييمات الفعالية العلاجية. كما أنه يتم تحديد الجرعات الخاصة بكل مريض بناء على حالته الصحية.
ا.د / محمود مهيوب البريهي
أستاذ مشارك كلية الصيدلة - جامعة صنعاء
قسم الصيدلانيات
Clinical Pharmacokinetics :
حركية الدواء السريرية مقرر من أهم مقررات كلية الصيدلة وتوصيف المقرر والمفردات تشمل إمتصاص الدواء والتوفر الحيوي وتوزيع الدواء وإستقلاب الدواء وطرد الدواء من الجسم و دراسة حركية الدواء من حيث تقييم أسس حركية الدواء الذي تحدد المدى المحدد لفعالية الدواء وتنظيم الجرعات و المتابعة المستمرة لنتائج الدواء مع المريض. دراسة حركية الدواء لها علاقة بصياغة وتحضير الدواء و تحليل الدواء وإستخدام الدواء ومعلومات الدواء الأساسية .
تطبيق مبادئ الحركة الدوائية في الحالات المرضية بشكل أساسي يركز هذا المقرر على نواحي وأسس الحركة الدوائية في اختيار الجرعات الدوائية المناسبة لكل مريض على النحو الأمثل. يناقش أيضا مبادئ الحركة الدوائية السريرية وتطبيقاتها في علاج الأمراض المختلفة كما يشير إلى التغيرات في حركية الدواء نتيجة للحالات المرضية بحيث يتم التركيز على متابعة تراكيز الدواء في الدم والطرق المتبعة في تخصيص الجرعات للمرضى وتأثير ذلك من الناحية العلاجية.
يتضمن هذا المقرر تعليم مبادئ حركية الدواء السريرية والمساعدة في تحديد نظام الجرعات وتقييمات الفعالية العلاجية. كما أنه يتم تحديد الجرعات الخاصة بكل مريض بناء على حالته الصحية.
ا.د / محمود مهيوب البريهي
أستاذ مشارك كلية الصيدلة - جامعة صنعاء
قسم الصيدلانيات
Clinical Pharmacokinetics
Course Denoscription:
Clinical Pharmacokinetics is designed to educate pharmacy students in the principles of pharmacokinetics parameters and how they assist in dosage regimen design and therapeutic efficacy evaluations.
Aims:
- To know pharmacokinetic terms and parameters .
- To know dosing information, therapeutic range, relevant pharmacokinetic equations.
Outcomes:
The students will be able to understand the effects of diseases states and conditions on the pharmacokinetics and dosing of specific drugs. It provides the students with the principles of dosing the patients more rationally and safely.
https://news.1rj.ru/str/CLINICPHARMA
Course Denoscription:
Clinical Pharmacokinetics is designed to educate pharmacy students in the principles of pharmacokinetics parameters and how they assist in dosage regimen design and therapeutic efficacy evaluations.
Aims:
- To know pharmacokinetic terms and parameters .
- To know dosing information, therapeutic range, relevant pharmacokinetic equations.
Outcomes:
The students will be able to understand the effects of diseases states and conditions on the pharmacokinetics and dosing of specific drugs. It provides the students with the principles of dosing the patients more rationally and safely.
https://news.1rj.ru/str/CLINICPHARMA
Telegram
PPDPROGRAM-CLINICAL PHARMACOKINETICS
PHARMACY PROFESSION DEVELOPMENT PROGRAM
PROF/MAHMOUD MAHYOOB ALBURYHI
PROF/MAHMOUD MAHYOOB ALBURYHI
CLINICAL PHARMACOKINETICS:
مفاهيم في حركية الدواء السريرية سوف يتم توضيحها بصورة مختصرة مبسطة في الأساسيات ثم ننتقل إلى شرح تفاصيل المفردات الأساسية في حركية الدواء السريرية والتطبيق العملي ل أسس حركية الدواء ⬇️
https://news.1rj.ru/str/CLINICPHARMA
مفاهيم في حركية الدواء السريرية سوف يتم توضيحها بصورة مختصرة مبسطة في الأساسيات ثم ننتقل إلى شرح تفاصيل المفردات الأساسية في حركية الدواء السريرية والتطبيق العملي ل أسس حركية الدواء ⬇️
https://news.1rj.ru/str/CLINICPHARMA
Telegram
PPDPROGRAM-CLINICAL PHARMACOKINETICS
PHARMACY PROFESSION DEVELOPMENT PROGRAM
PROF/MAHMOUD MAHYOOB ALBURYHI
PROF/MAHMOUD MAHYOOB ALBURYHI